Prairiewood Capital’s Supernus Pharmaceuticals SUPN Stock Holding History

Prairiewood Capital’s Portfolio SUPN Stock Details SUPN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-43,345	Closed	-$1.4M	–	72
2022 Q1	$1.4M	Sell	43,345 -1,070	-2%	-$32.8K	0.98%	24
2021 Q4	$1.29M	Sell	44,415 -882	-2%	-$26.8K	1.02%	24
2021 Q3	$1.21M	Sell	45,297 -686	-1%	-$18.4K	0.99%	25
2021 Q2	$1.42M	Hold	45,983	–	–	1.21%	21
2021 Q1	$1.2M	Buy	45,983 +1,808	+4%	+$50.6K	1.1%	23
2020 Q4	$1.11M	Buy	+44,175	New	+$951K	1.13%	24

Other funds holding SUPN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

GKIM

GW&K Investment Management Boston, Massachusetts $11.3B AUM 31.98% 1-Year Est. Return

SIMG

Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

ACB

Aristotle Capital Boston Boston, Massachusetts $1.61B AUM 19.82% 1-Year Est. Return

Prairiewood Capital's SUPN Position: Q2 2022 in Review

Prairiewood Capital sold out of Supernus Pharmaceuticals (SUPN) in Q2 2022, closing a stake of 43,345 shares — an estimated $1.4M sold.

Prairiewood Capital first reported a position in SUPN in Q4 2020 and held it in 6 quarters. The position peaked at $1.42M in Q2 2021. 225 funds tracked by Wall St. Rank hold SUPN as of Q2 2022.

Prairiewood Capital reported no remaining Supernus Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
Prairiewood Capital sold 43,345 Supernus Pharmaceuticals shares in Q2 2022, an estimated $1.4M.
Prairiewood Capital first reported a position in Supernus Pharmaceuticals in Q4 2020 and held it in 6 quarters.
Prairiewood Capital's Supernus Pharmaceuticals position peaked at $1.42M in Q2 2021.
225 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q2 2022.

Based on Prairiewood Capital's 13F filing for Q2 2022, filed 13 Jul 2022.